Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204654 | 0.90 | HRH4 (0.33) | ACLYHRH4PDE4APDE4BPDE4C | |
| SCHEMBL3202779 | 0.88 | LMNA (0.38) | ACLYHRH4 | |
| SCHEMBL3214943 | 0.88 | HRH4 (0.33) | ACLYHRH4 | |
| SCHEMBL3212622 | 0.87 | PDE4A (0.33) | ACLYHRH4PDE4A | |
| SCHEMBL7947884 | 0.86 | HRH4 (0.33) | ACLYHRH4PDE4A | |
| SCHEMBL3213223 | 0.85 | HRH4 (0.31) | ACLYHRH4 | |
| SCHEMBL3191879 | 0.84 | PARP15 (0.46) | HRH4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3203145 | 0.84 | PDE4D (0.37) | HRH4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3211858 | 0.84 | HRH4 (0.40) | HRH4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3207210 | 0.83 | TAAR1 (0.43) | ACLYHRH4PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | ACLY 2215/4885HSD17B10 440/4885HRH4 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.